Investigation of the Influence of Gender on Cardiovascular Function

This study is currently recruiting participants.
Verified March 2014 by Queen Mary University of London
Sponsor:
Information provided by (Responsible Party):
Amrita Ahluwalia, Queen Mary University of London
ClinicalTrials.gov Identifier:
NCT01582321
First received: April 18, 2012
Last updated: March 10, 2014
Last verified: March 2014
  Purpose

Inflammation is a key initiating and damaging factor in many illnesses including infection, arthritis and cancer but also of particular relevance to this study in diseases of the heart and blood vessels (i.e. cardiovascular disease). Much evidence now exists demonstrating that male sex increases ones risk of cardiovascular disease. More recent evidence demonstrates that inflammatory responses in females appear to dampened in comparison to age matched males. Since inflammation is thought to be a key initiating phenomenon in many cardiovascular disease states the investigators will examine the differences in acute inflammatory responses between the sexes in healthy volunteers and the impact this has on the function of blood vessels.


Condition Intervention Phase
Cardiovascular Function
Biological: Typhoid vaccine
Drug: Cantharidin
Phase 0

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Investigation of the Influence of Gender on Cardiovascular Function and Inflammation

Further study details as provided by Queen Mary University of London:

Primary Outcome Measures:
  • Comparison change in blister fluid total and differential leukocyte numbers (Part 1) [ Time Frame: 24, 72 h ] [ Designated as safety issue: No ]
    plasma and fluid collected from the blisters at 24 hours (acute phase) and 72 hours (resolution phase) after the cantharidin application will be analysed using standard laboratory techniques including flow cytometry

  • Flow-mediated dilatation (Part 2) [ Time Frame: 0, 24, 48 h ] [ Designated as safety issue: No ]
    Flow mediated dilatation of the brachial artery will be assessed using ultrasound will be measured at time 0, 24 and 48h. At the 16h timepoint a single typhoid vaccination will be administered in the arm or buttock.


Secondary Outcome Measures:
  • Blood pressure (Part 1) [ Time Frame: 0, 48, 72 h ] [ Designated as safety issue: No ]
    Blood pressure will be measured every 15 minutes for 1 hour

  • Platelet reactivity (Part 2) [ Time Frame: 0, 24 and 48h ] [ Designated as safety issue: No ]
    Blood will be collected and platelet reactivity assessed using impedance aggreometry

  • Platelet activation (Part 2) [ Time Frame: 0,24 and 48h ] [ Designated as safety issue: No ]
    Blood will be collected and platelet p-selectin and platelet-monocyte expression determined using flow cytometry

  • Arterial stiffness (Part 2) [ Time Frame: 0, 24 and 48h ] [ Designated as safety issue: No ]
    The speed of blood pressure waves will be measured to give a pulse wave velocity measure for the aorta.

  • Inflammatory cell expression (Part 1 and 2) [ Time Frame: 0, 48, 72h part 1, 0, 24 and 48h part 2 ] [ Designated as safety issue: No ]
    Blood will be collected and inflammatory cell populations determined using flow cytometry

  • Blood inflammatory molecule expression (Part 1 and 2) [ Time Frame: 0, 48, 72 h part 1, 0, 24 and 48h part 2, ] [ Designated as safety issue: No ]
    Plasma will be collected for assessment of inflammatory markers


Estimated Enrollment: 56
Study Start Date: March 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part 1 Male
16 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
Drug: Cantharidin
0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
Other Name: Cantharidin, cantharone 0.1%
Experimental: Part 1 Female
16 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
Drug: Cantharidin
0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
Other Name: Cantharidin, cantharone 0.1%
Experimental: Part 2 Male
12 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
Biological: Typhoid vaccine
The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
Other Name: Typhim Vi®
Experimental: Part 2 Female
12 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
Biological: Typhoid vaccine
The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
Other Name: Typhim Vi®

Detailed Description:

We now know that one of the earliest events involved in precipitating disease of the heart and blood vessels is the phenomenon of inflammation and that this inflammation is a key process involved in dampening the protective nature of the inner lining (the endothelium) of the blood vessel wall, called endothelial dysfunction. In healthy arteries the endothelium releases a number of factors that maintain the health of the blood vessel. These factors act to keep the blood vessel in an open and dilated state and prevent the furring up of the vessel by actively inhibiting the cell components of the blood from collecting at the endothelium and blocking the flow of blood through the artery. Recent research in animals has demonstrated that one of the key components of inflammation i.e. the attraction of white cells, is reduced in females compared to males and that this is due to a reduced expression of key proteins called 'adhesion molecules', an in particular a molecule called P-selectin, on the endothelium. We now wish to determine whether similar differences in white cell attraction and adhesion molecules exist between the sexes in humans and whether these differences might underlie differences in endothelial function.

To investigate this possibility we will conduct a study in two parts, using well validated models of acute inflammation in healthy volunteers.

Part 1 To determine whether responses to inflammation differ between sexes in part 1 we will use a cantharidin-induced model of acute inflammation. Previous published studies have shown when cantharidin is applied to the skin it causes acantholysis and blister formation. It is a safe, reproducible technique with no permanent scarring or ill-effects. We will study the effects on inflammatory responses by measuring the levels of cells and inflammatory mediators in blister fluids, urine and plasma. Participants will given two blisters that will be harvested at 24 hours (acute phase) and 72 hours (resolution phase) after cantharidin application. The effects of inflammation on blood vessels will also be studied through non invasive blood pressure measurements.

Part 2 To determine whether susceptibility to inflammation-induced endothelial dysfunction is distinct between the sexes in part 2 we will use typhoid vaccine to induce mild inflammation throughout the body including the blood vessels. Previous published studies have shown that vaccination induces an acute inflammation that results in a temporary (reversed within 48h) dysfunction of the endothelium that can be measured using a range of non-invasive techniques called ultrasound flow-mediated dilatation and pulse wave velocity. We will use these techniques together with biochemical measurements to determine possible associations of endothelial dysfunction with specific inflammatory factors. In particular we will investigate the possibility that differences in the expression of the adhesion molecule P-selectin might have a role to play in differences between the sexes.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Healthy subjects aged 18-45 who have volunteered themselves and are willing to sign the consent form.

Exclusion Criteria:

  1. Healthy subjects unwilling to consent
  2. History of hypertension, diabetes or hypertensive on BP measurement
  3. Pregnant, or any possibility that a subject may be pregnant unless in the latter case a pregnancy test is performed with a negative result
  4. History of any serious illnesses, including recent infections or trauma
  5. Subjects taking systemic medication (other than the oral contraceptive pill)
  6. Subjects with self-reported use of mouthwash or tongue scrapes
  7. Subjects with recent or current antibiotic use
  8. Subjects with a history, or recent treatment of (within last 3 months) of any oral condition (excluding caries), including gingivitis, periodontitis and halitosis.
  9. Subjects that have recently participated (preceding 3 months) in any clinical studies involving administration of an inflammogen.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01582321

Contacts
Contact: Amrita Ahluwalia, BSc PhD 0207 882 8377 a.ahluwalia@qmul.ac.uk
Contact: Amy Roberston, BSc, RN 0207 882 8931 amy.robertson@qmul.ac.uk

Locations
United Kingdom
William Harvey Heart Centre, Barts & The London Medical School Recruiting
London, United Kingdom, EC1M 6BQ
Principal Investigator: Amrita Ahluwalia, BSc PhD         
Sub-Investigator: Shanti Velmurugan, MBBS MRCP         
Sub-Investigator: Rayomand Khambata, BSc PhD         
Sub-Investigator: Vikas Kapil, MBBS MRCP         
Sub-Investigator: Adrian J Hobbs, BSc PhD         
Sub-Investigator: Krishnaraj Rathod, MBBS MRCP         
Sub-Investigator: Amy C Robertson, BSc, RN         
Sponsors and Collaborators
Queen Mary University of London
Investigators
Principal Investigator: Amrita Ahluwalia, BSC PhD Queen Mary University of London
  More Information

Additional Information:
PIS  This link exits the ClinicalTrials.gov site

Publications:
Responsible Party: Amrita Ahluwalia, Professor of Vascular Pharmacology, Queen Mary University of London
ClinicalTrials.gov Identifier: NCT01582321     History of Changes
Other Study ID Numbers: 11/LO/2038
Study First Received: April 18, 2012
Last Updated: March 10, 2014
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Queen Mary University of London:
vascular ultrasound
flow cytometry
platelet aggregation

Additional relevant MeSH terms:
Cantharidin
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 16, 2014